Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxaliplatin - Dr Reddy's Laboratories/Pfizer/Sanofi/Yakult Honsha

Drug Profile

Oxaliplatin - Dr Reddy's Laboratories/Pfizer/Sanofi/Yakult Honsha

Alternative Names: 1 OHP; 1670 RB7; Ai Heng; Aiheng; Dacotin; Dacplat; Diaminocyclohexane oxalatoplatinum; Eloxatin; Eloxatine; Elplat; JM-83; NSC 266046; Oxalatoplatin; Oxalatoplatinum; RP 54780; SR 96669

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nagoya University
  • Developer Alliance for Clinical Trials in Oncology; Beth Israel Deaconess Medical Center; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Debiopharm; Pfizer; Sanofi; University of California at Irvine; University of Southern California; University of Texas M. D. Anderson Cancer Center; Yakult Honsha
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer
  • Registered Liver cancer; Pancreatic cancer
  • Phase II Germ cell and embryonal neoplasms; Germ cell cancer; Intestinal cancer; Oesophageal cancer; Ovarian cancer; Testicular cancer; Uterine cancer
  • No development reported Head and neck cancer
  • Discontinued Acute myeloid leukaemia; Breast cancer; Diffuse large B cell lymphoma; Myelodysplastic syndromes; Nasopharyngeal cancer; Non-small cell lung cancer

Most Recent Events

  • 09 Sep 2022 Adverse events and efficacy data from a phase III ACHIEVE-2 trial in Colon cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 17 Feb 2021 No recent reports on development identified - Phase-II for Head and neck cancer (Adjuvant therapy) in USA (IV) (NCT00256308)
  • 31 May 2019 National Cancer Institute and Jonsson Comprehensive Cancer Center plans a phase I/II trial for Pancreatic cancer (Combination therapy) in USA (IV) (NCT03970252)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top